Neuroendocrine Tumors- Pipeline Insight, 2023

Neuroendocrine Tumors- Pipeline Insight, 2023

DelveInsight’s, “Neuroendocrine Tumors- Pipeline Insight, 2023,” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Neuroendocrine Tumors Understanding

Neuroendocrine Tumors: Overview

A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have a specific effect on the activity of other organs or cells in the body. Most NETs take years to develop and grow slowly. However, some NETs can be fast-growing. NETs can also begin in other organs. In about 15% of cases, a primary site cannot be found. Sometimes, NETs may develop in or on the adrenal glands. NETs can begin in any part of the body, including: Gastrointestinal (GI) tract. NETs develop most commonly in the GI tract, specifically in the large intestine (20%), small intestine (19%), and appendix (4%). The GI tract plays a central role in digesting foods and liquid and in processing waste. GI tract NETs used to be called carcinoid tumors. The lung is the second most common location of NETs. About 30% of NETs occur in the bronchial system, which carries air to the lungs. Lung NETs also used to be called carcinoid tumors. Approximately 7% of NETs can develop in the pancreas, a pear-shaped gland located in the abdomen between the stomach and the spine. Pancreas NETs used to be called islet cell tumors. The diagnosis of a NET requires a coordinated multidisciplinary effort involving medical oncologists, surgeons, interventional radiologists and pathologists. Results from pathology testing, hormonal testing, and diagnostic and functional imaging are integrated to form a comprehensive diagnostic picture. Individualized treatment plans are formulated based on tumour factors such as site, stage, grade, differentiation and symptoms, and patient factors such as age and comorbidities.

""Neuroendocrine Tumors- Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neuroendocrine Tumors pipeline landscape is provided which includes the disease overview and Neuroendocrine Tumors treatment guidelines. The assessment part of the report embraces, in depth Neuroendocrine Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neuroendocrine Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neuroendocrine Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Neuroendocrine Tumors.

Neuroendocrine Tumors Emerging Drugs Chapters

This segment of the Neuroendocrine Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neuroendocrine Tumors Emerging Drugs

ITM-11: ITM Solucin

ITM-11, ITM’s therapeutic radiopharmaceutical candidate being investigated in the phase III clinical studies COMPETE and COMPOSE, consists of two components: the medical radioisotope no-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors. Edotreotide binds to these receptors and places the medical radioisotope n.c.a. lutetium-177 directly onto the diseased neuroendocrine cells so that it accumulates at the tumor site. N.c.a. lutetium-177 is internalized into the tumor cells and decays, releasing medical radiation (ionizing β-radiation) with a maximum radius of 1.7 mm and destroying tumor tissue. The highly precise localization can result in the healthy tissue surrounding the targeted tumor being minimally affected. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

Alphamedix: RadioMedix

AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb that serves as an in vivo generator of alpha-emitting particles. 212Pb isotope is particularly suitable for SSTR therapy applications based upon its half-life, energy, and decay properties. The drug is currently in Phase II stage of clinical trial evaluation to treat Neuroendocrine Tumors.

BI 764532: Boehringer Ingelheim

BI 764532 is a delta-like ligand 3 (DLL3)/CD3 T cell engaging bispecific antibody. DLL3 is expressed on the cell surface of many SCLC and NEC tumors, but not on normal cells. In preclinical studies, BI 764532 induced cytotoxicity of DLL3-positive cells and showed anti-tumor activity in animal models. The T-cell engager BI 764532 binds to DLL3 and cells of the immune system simultaneously, resulting in the death of tumor cells. The drug is currently in Phase I stage of clinical trial evaluation to treat Neuroendocrine Tumors.

Further product details are provided in the report……..

Neuroendocrine Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Neuroendocrine Tumors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neuroendocrine Tumors

There are approx. 55+ key companies which are developing the therapies for Neuroendocrine Tumors. The companies which have their Neuroendocrine Tumors drug candidates in the most advanced stage, i.e. phase III include, ITM Solucin

Phases

DelveInsight’s report covers around 60+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neuroendocrine Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Neuroendocrine Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neuroendocrine Tumors drugs.

Neuroendocrine Tumors Report Insights

Neuroendocrine Tumors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Neuroendocrine Tumors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Neuroendocrine Tumors drugs?

How many Neuroendocrine Tumors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neuroendocrine Tumors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neuroendocrine Tumors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Neuroendocrine Tumors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Jiangsu Hengrui Medicine

MedImmune

Genentech

Merck & Co

Pfizer

Takeda Oncology

Hutchison MediPharma

Provectus Biopharmaceuticals

NanoValent Pharmaceuticals

Camurus

ITM Solucin

Radiomedix, Inc.

Orano Med LLC

Clarity Pharmaceuticals

TaiRx

Peloton Therapeutics

RayzeBio

Ascentage Pharma

Debiopharm

Boehringer Ingelheim

Roche

Ipsen

Medelis Inc.

Exelixis

EpicentRx, Inc.

Tarveda Therapeutics

Teclison Ltd.

Novatek Pharmaceuticals

Phanes Therapeutics

Fujifilm Pharmaceuticals

Jazz Pharmaceuticals

23andMe, Inc.

Celgene

Crinetics Pharmaceuticals Inc.

POINT Biopharma

Key Products

VVZ-149

177Lu-edotreotide PRRT

Axitinib

AlphaMedix

64Cu MeCOSar Octreotate

Foslinanib

Belzutifan

Actinium-225 Dotate

Pelcitoclax

Debio 4126 controlled release

BI 764532

RO7616789

Satoreotide trizoxetan

CAM-2029

RRx-001

Lenvatinib

PEN-221

Belzutifan

Tirapazamine

Sunitinib

NP-101

PT217

FF-10850

Lurbinectedin

23ME-00610

BLU-667

CC-223

Paltusotine

TAK 580

PV-10

NV 103